Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

APAiyana ParkerMDMaria DolaherWLWon‐Ho Lee

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals CAR T cell profiles linked to toxicity and response outcomes in multiple myeloma patients.

Key Points

  • This research aims to understand the efficacy and toxicity mechanisms of anti-BCMA CAR-T therapies in multiple myeloma.
  • Conducted a retrospective study with samples from multiple myeloma patients treated with cilta-cel, ide-cel, or anito-cel.
  • Performed single-cell RNA sequencing and paired T cell receptor sequencing.
  • Analyzed T cell profiles and association with movement and neurocognitive toxicities.
  • Identified elevated CAR+ T cell populations linked to neurocognitive toxicities in cilta-cel treated patients.
  • Found differences in T cell profiles that correlate with response outcomes in cilta-cel versus ide-cel and anito-cel patients.
  • Developed an MNT signature score associated with CAR T cell profiles at D14 and monitoring for future interventions.

Cite This Study

Parker et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e501https://doi.org/10.1182/blood-2025-503
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma2025
  2. 2Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma2026
  3. 3Abstract 3616: <i>In vivo</i> expansion patterns of anti-BCMA CAR T-cell in relapsed/refractory multiple myeloma: Comparative immunomonitoring of idecabtagene vicleucel and ciltacabtagene autoleucel2024
  4. 4The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma2025 · 1 citations
  5. 5Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma2024 · 41 citations